Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma
A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma (MAPPING-ACC)
We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 114 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT07507578 on ClinicalTrials.gov |
What this trial studies
This observational project applies multi-omics profiling (tumor genomics, transcriptomics, and blood-based biomarkers) to tumors and matched metastases from people with metastatic head and neck adenoid cystic carcinoma (ACC). Investigators will compare primary tumor biology to metastatic lesions and link molecular findings to published clinical risk groups derived from a nomogram. The study will also examine whether tumor biological type varies by metastatic site or timing and whether circulating biomarkers (including cell-free DNA and small RNAs) reflect tumor biology and treatment response. All procedures are correlative and samples are collected alongside standard-of-care treatments.
Who should consider this trial
Good fit: Ideal candidates are adults with pathologically confirmed primary ACC of the head and neck who have unequivocal distant metastases and can provide tumor tissue and blood samples and comply with study procedures.
Not a fit: Patients without distant metastases, with primary ACC outside the head and neck, or those lacking sufficient tissue or prior clinical data are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, the findings could help predict disease course and guide more personalized treatment and monitoring for people with metastatic head and neck ACC.
How similar studies have performed: Previous research has identified molecular subtypes in ACC and multi-omics approaches have shown promise in cancer profiling, but applying these methods specifically to progression patterns in metastatic head and neck ACC is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologic diagnosis of ACC * Primary ACC arising from the head and neck * Unequivocal clinical and/or radiological evidence of metastatic disease * Patient ability and availability to comply with study protocol procedures. Exclusion Criteria: * ACC patients with local and/or regional recurrence without distant metastases * Primary ACC arising from any non-head and neck region (e.g., breast, lung, skin etc) * Insufficient data about previous medical history.
Where this trial is running
Milan
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Lisa Licitra — Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Study coordinator: Lisa Licitra
- Email: lisa.licitra@istitutotumori.mi.it
- Phone: +39 02 2390 2810
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.